REATA PHARMACEUTICALS INC Quarterly Nonoperating Income (Expense) in USD from Q1 2015 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Reata Pharmaceuticals Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2015 to Q2 2023.
  • Reata Pharmaceuticals Inc Nonoperating Income (Expense) for the quarter ending June 30, 2023 was $285M.
  • Reata Pharmaceuticals Inc Nonoperating Income (Expense) for the twelve months ending June 30, 2023 was $265M.
  • Reata Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2022 was -$33.9M, a 36.2% increase from 2021.
  • Reata Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2021 was -$53.1M, a 21% decline from 2020.
  • Reata Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2020 was -$43.9M, a 789% decline from 2019.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $265M $285M +$295M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$29.8M -$5.66M +$4.11M +42.1% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-10
Q4 2022 -$33.9M -$6.03M +$7.56M +55.6% Oct 1, 2022 Dec 31, 2022 10-K 2023-02-24
Q3 2022 -$41.5M -$8.52M +$5.24M +38.1% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-08
Q2 2022 -$46.7M -$9.57M +$3.65M +27.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$50.3M -$9.77M +$2.78M +22.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$53.1M -$13.6M -$1.65M -13.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-24
Q3 2021 -$51.5M -$13.8M -$2.59M -23.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$48.9M -$13.2M +$3.77M +22.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$52.7M -$12.6M -$8.74M -229% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$43.9M -$11.9M -$9.38M -366% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$34.5M -$11.2M -$10.1M -936% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$24.4M -$17M -$16.3M -2324% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$8.16M -$3.81M -$3.21M -536% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$4.94M -$2.56M -$1.91M -295% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$3.03M -$1.08M +$188K +14.9% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$3.22M -$701K +$852K +54.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$4.07M -$600K -$426K -245% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$3.64M -$649K -$501K -339% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-19
Q3 2018 -$3.14M -$1.27M -$977K -338% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-19
Q2 2018 -$2.16M -$1.55M -$1.16M -293% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-19
Q1 2018 -$1.01M -$174K -$250K -329% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-19
Q4 2017 -$756K -$148K -$249K -247% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$507K -$289K -$351K -566% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$156K -$395K -$423K -1511% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 $267K $76K +$53K +230% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 $214K $101K +$94K +1343% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-02
Q3 2016 $120K $62K +$53K +589% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-02
Q2 2016 $67K $28K +$20K +250% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-02
Q1 2016 $47K $23K +$15K +188% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-02
Q4 2015 $32K $7K Oct 1, 2015 Dec 31, 2015 10-K 2017-03-03
Q3 2015 $9K Jul 1, 2015 Sep 30, 2015 10-K 2017-03-03
Q2 2015 $8K Apr 1, 2015 Jun 30, 2015 10-K 2017-03-03
Q1 2015 $8K Jan 1, 2015 Mar 31, 2015 10-K 2017-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.